Drug intelligence / Profile preview

LK-01

Development stage
Unknown
Lead developer
LiveKidney.Bio
Modality
Stem Cell Therapies → Cell Therapies, Hydrogel Systems → Drug Delivery Systems
Administration
Subcutaneous
01

Overview

LK-01 is an investigational cell therapy developed by LiveKidney.Bio, consisting of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) encapsulated in a proprietary, cell-shielding hydrogel formulation. Administered via subcutaneous injection, the therapy is designed to provide a continuous, sustained release of therapeutic bioactive compounds and immunomodulatory factors. LK-01 aims to address the hallmarks of aging and autoimmune disease by modulating the immune system, reducing inflammation and fibrosis, and enhancing mitochondrial activity to improve kidney function. It is primarily being developed for autoimmune-related kidney diseases, including lupus nephritis and IgA nephropathy, as well as systemic conditions like rheumatoid arthritis and systemic sclerosis.

Other names
LK-01-LiveKidney.Bio-cell therapy (MSC-based)-subcutaneous (SC)-lupus nephritis-IgA nephropathy-rheumatoid arthritis-systemic sclerosis

Beyond the preview

Go deeper on LK-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LK-01.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call